(Date:9/5/2008)...swire-FirstCall/ -- BioSpecifics,Technologies Corp...company,developing first in class collagenase base...agreement to significantly improve the deal terms ...onie,s disease by buying down its,future royalty o...ifics has modified its previously announced agreem...
(Date:9/5/2008)...ed to Expand Business Development Efforts, SALT L...c., a company,focused on the development of molecu...in the spine care market, announced today that Joe...the company,s new Vice President of,Strategic Init...al Biotech,s global efforts to,identify, evaluate,...
(Date:9/4/2008)...Newswire-FirstCall/ -- BioForm Medical,Inc. (Nasd...for the fourth,quarter and full fiscal year ended ...e quarter ended June 30, 2008 as compared to $15.4...ncrease of $1.3 million or 8.4%.,The net loss was ...as,compared to a net loss of $4.9 million for the ...
(Date:9/4/2008)... 4 /-, - Prevenar Vaccine ...ne-Preventable Cause of Death in Young Children Wo...e Republic of Ireland have,initiated national immu...hildren against pneumococcal disease by adding Pre...ine, Adsorbed), also called PCV7, to their,nationa...
Breaking Biology Technology:BioSpecifics Technologies Corp. Buys Down Royalties for Peyronie's Disease 2Axial Biotech appoints new Vice President of Strategic Initiatives 2BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 2BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 3BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 4BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 5BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 6BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 7BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 8BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 9Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules 2Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules 3...nology have provided people with many items such a...es with digital audio capabilities. Technology is ...considered fantasy 10 years ago are now taken for ...nies must consider and understand how technology m... with other parties, especially in areas with rapi...
...chick co-authored this commentary with Michael J. ...ciate with Whyte Hirschboeck Dudek in Madison. , ...ortant University of Wisconsin stem cell patents... a strong likelihood that the Wisconsin Alumni Re...ights, even if some of its claims are changed or c...
...s writing a series of articles on raising capital ...rm sheet. , , Most of the time when raising equi...hat is referred to as a term sheet . When dealin...mpany to produce the initial term sheet. , ,Someti...iate the initial term sheet, especially if one of ...
...everyone will be famous for 15 minutes, couldn,t i...l networks, and Web 2.0 might have on his predicti...5 minutes - but just 15 minutes. Maybe not even th...as time for these days, at least in the echo chamb...fter coming back from a near three-week holiday ou...
Other Biology Technology:Making deals with evolving technologies in mind 2Making deals with evolving technologies in mind 3Making deals with evolving technologies in mind 4Making deals with evolving technologies in mind 5WARF is likely to hold on to stem cell patent rights 2WARF is likely to hold on to stem cell patent rights 3WARF is likely to hold on to stem cell patent rights 4WARF is likely to hold on to stem cell patent rights 5WARF is likely to hold on to stem cell patent rights 6WARF is likely to hold on to stem cell patent rights 7WARF is likely to hold on to stem cell patent rights 8Capital-raising term sheets for angels and venture capitalists 2Capital-raising term sheets for angels and venture capitalists 3Capital-raising term sheets for angels and venture capitalists 4Capital-raising term sheets for angels and venture capitalists 5On the Web, attention spans shrink, the need for value rises 2On the Web, attention spans shrink, the need for value rises 3...h exhibit the remarkable ability to hunt for insec...recisely aimed streams of water that knock prey on...e thought to be all-or-none in quality, but resear...tion in the archerfish,s hunting strategy that she...has evolved. The findings are reported by Thomas S...
...rs at the University of Rochester may have answere... can it be that our neurons, which are responsible...tterly random ways? , In the November issue of Nat...he brain,s cortex uses seemingly chaotic, or "nois...al world--and that this noise dramatically enhance...
...o must stay awake for long shifts ?soldiers, pilot...s ?may take comfort from new research showing that...in the brain may ward off the sleep urge. , The r...s Hospital Boston and the University of Helsinki (...tions about sleep and finds that nitric oxide prod...
...rs at Johns Hopkins have figured out how one parti...helps the brain remember things longer than an hou...in the Nov. 9 issue of Neuron. , The protein, call...iors ranging from song learning in birds to rodent...one culprit behind certain long-term memory-based ...
Other Biology News:Archerfish tune their shots to universal properties of prey adhesion 2Mysterious 'neural noise' actually primes brain for peak performance 2Mysterious 'neural noise' actually primes brain for peak performance 3Need to pull an all-nighter? 2Hopkins researchers discover how brain protein might control memory 2Hopkins researchers discover how brain protein might control memory 3Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes.
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected.
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3
Biology Products: